Stock News

Cwm Trimmed Myriad Genetics (MYGN) Position By $2.54 Million; Exelixis Has 1.57 Sentiment

Myriad Genetics, Inc. (NASDAQ:MYGN) Logo

Exelixis Inc (EXEL) investors sentiment increased to 1.57 in Q4 2017. It’s up 0.34, from 1.23 in 2017Q3. The ratio has improved, as 144 hedge funds opened new and increased positions, while 92 sold and reduced their holdings in Exelixis Inc. The hedge funds in our database now hold: 232.85 million shares, down from 237.25 million shares in 2017Q3. Also, the number of hedge funds holding Exelixis Inc in top ten positions was flat from 3 to 3 for the same number . Sold All: 26 Reduced: 66 Increased: 85 New Position: 59.

Cwm Llc decreased Myriad Genetics Inc (MYGN) stake by 19.84% reported in 2017Q4 SEC filing. Cwm Llc sold 74,767 shares as Myriad Genetics Inc (MYGN)’s stock declined 14.14%. The Cwm Llc holds 302,093 shares with $10.38M value, down from 376,860 last quarter. Myriad Genetics Inc now has $2.00 billion valuation. The stock decreased 1.89% or $0.55 during the last trading session, reaching $28.58. About 333,370 shares traded. Myriad Genetics, Inc. (NASDAQ:MYGN) has risen 52.68% since April 25, 2017 and is uptrending. It has outperformed by 41.13% the S&P500.

The stock decreased 1.64% or $0.34 during the last trading session, reaching $20.4. About 2.34M shares traded. Exelixis, Inc. (EXEL) has risen 5.01% since April 25, 2017 and is uptrending. It has underperformed by 6.54% the S&P500.

Ratings analysis reveals 100% of Exelixis’s analysts are positive. Out of 2 Wall Street analysts rating Exelixis, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. EXEL was included in 2 notes of analysts from September 15, 2016. The rating was upgraded by Piper Jaffray to “Overweight” on Monday, October 10. On Thursday, September 15 the stock rating was maintained by Stifel Nicolaus with “Buy”.

Analysts await Exelixis, Inc. (NASDAQ:EXEL) to report earnings on May, 2 after the close. They expect $0.12 EPS, up 140.00% or $0.07 from last year’s $0.05 per share. EXEL’s profit will be $35.60 million for 42.50 P/E if the $0.12 EPS becomes a reality. After $0.12 actual EPS reported by Exelixis, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Meditor Group Ltd holds 64.5% of its portfolio in Exelixis, Inc. for 16.48 million shares. Rhenman & Partners Asset Management Ab owns 756,214 shares or 3.11% of their US portfolio. Moreover, Pura Vida Investments Llc has 1.8% invested in the company for 80,000 shares. The Massachusetts-based Bogle Investment Management L P De has invested 1.57% in the stock. Smith Asset Management Group Lp, a Texas-based fund reported 865,880 shares.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company has market cap of $6.05 billion. The companyÂ’s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. It has a 41.38 P/E ratio. The Company’s CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program.

Since January 1, 0001, it had 0 buys, and 11 insider sales for $6.62 million activity.

Analysts await Myriad Genetics, Inc. (NASDAQ:MYGN) to report earnings on May, 1. They expect $0.27 earnings per share, 0.00% or $0.00 from last year’s $0.27 per share. MYGN’s profit will be $18.86 million for 26.46 P/E if the $0.27 EPS becomes a reality. After $0.31 actual earnings per share reported by Myriad Genetics, Inc. for the previous quarter, Wall Street now forecasts -12.90% negative EPS growth.

Since December 11, 2017, it had 0 insider purchases, and 7 selling transactions for $5.48 million activity. DREISMANN HEINRICH had sold 6,000 shares worth $201,000 on Monday, December 11. On Thursday, December 14 GILBERT WALTER PHD sold $248,925 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) or 7,500 shares. King Gary A. had sold 34,445 shares worth $1.37 million on Monday, January 22. The insider MARSH RICHARD M sold $1.53 million.

Cwm Llc increased Ishares Tr (VLUE) stake by 50,932 shares to 73,888 valued at $6.18 million in 2017Q4. It also upped F M C Corp (NYSE:FMC) stake by 3,863 shares and now owns 15,912 shares. Halliburton Co (NYSE:HAL) was raised too.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *